MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Alkermes PLC

Gesloten

SectorGezondheidszorg

29.22 -0.48

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

29.01

Max

29.57

Belangrijke statistieken

By Trading Economics

Inkomsten

-124M

22M

Verkoop

-123M

307M

K/W

Sectorgemiddelde

14.138

39.857

EPS

0.291

Winstmarge

7.329

Werknemers

1,800

EBITDA

-168M

14M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+38.08% upside

Dividenden

By Dow Jones

Volgende Winsten

29 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-832M

5B

Vorige openingsprijs

29.7

Vorige sluitingsprijs

29.22

Nieuwssentiment

By Acuity

50%

50%

154 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Alkermes PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 jul 2025, 21:01 UTC

Winsten

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 jul 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

18 jul 2025, 20:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

18 jul 2025, 20:50 UTC

Marktinformatie
Winsten

Basic Materials Roundup: Market Talk

18 jul 2025, 20:46 UTC

Winsten

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 jul 2025, 20:39 UTC

Acquisities, Fusies, Overnames

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 jul 2025, 20:36 UTC

Winsten

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 jul 2025, 20:16 UTC

Acquisities, Fusies, Overnames

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 jul 2025, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

18 jul 2025, 20:02 UTC

Marktinformatie

Gold Higher to Close Out Week -- Market Talk

18 jul 2025, 19:14 UTC

Marktinformatie

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 jul 2025, 19:06 UTC

Marktinformatie

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 jul 2025, 18:24 UTC

Winsten

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 jul 2025, 18:19 UTC

Winsten

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 jul 2025, 18:11 UTC

Acquisities, Fusies, Overnames

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 jul 2025, 18:11 UTC

Winsten

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 jul 2025, 17:35 UTC

Marktinformatie

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 jul 2025, 16:29 UTC

Marktinformatie

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 jul 2025, 16:28 UTC

Acquisities, Fusies, Overnames

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 jul 2025, 16:22 UTC

Winsten

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 jul 2025, 16:20 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

18 jul 2025, 16:20 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

18 jul 2025, 16:20 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

18 jul 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

18 jul 2025, 16:20 UTC

Marktinformatie
Winsten

Basic Materials Roundup: Market Talk

18 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

18 jul 2025, 16:04 UTC

Winsten

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 jul 2025, 15:58 UTC

Marktinformatie

Global Equities Roundup: Market Talk

18 jul 2025, 15:58 UTC

Marktinformatie

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 jul 2025, 15:47 UTC

Marktinformatie
Winsten

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Peer Vergelijking

Prijswijziging

Alkermes PLC Prognose

Koersdoel

By TipRanks

38.08% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 40.54 USD  38.08%

Hoogste 46 USD

Laagste 34 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Alkermes PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

14 ratings

9

Buy

5

Hold

0

Sell

Technische score

By Trading Central

27.95 / 30.91Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

154 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.